Floatz logo

Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer

Nonpapillary Renal Cell Carcinoma

Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

111 Active assets in the Nonpapillary Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Girentuximab
Massachusetts General Hospital
Phase 3BB
Clostridium Butyricum Miyairi 588
City of Hope Medical Center
Phase 3BB
Pazopanib
Academic and Community Cancer Research United
Phase 4BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB
Cabozantinib
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer is also rated in:

skin squamous cell carcinomaActive
BB
Indicative · Phase 3
66 / 100
View asset →
lung cancerActive
BB
Indicative · Phase 2/3
65 / 100
View asset →
plasma cell myelomaActive
B
Indicative · Phase 2
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →